<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00575627</url>
  </required_header>
  <id_info>
    <org_study_id>pNNALTHCV</org_study_id>
    <secondary_id>NNALT</secondary_id>
    <nct_id>NCT00575627</nct_id>
  </id_info>
  <brief_title>Pegylated-Interferon and Ribavirin in Hepatitis C Patients With Persistently Normal Alanine Aminotransferase Levels</brief_title>
  <official_title>Treatment of Chronic Hepatitis C Patients With Persistently Normal Alanine Aminotransferase Levels With Peginterferon α-2a (40 kDa) Plus Ribavirin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Turin, Italy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Turin, Italy</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with chronic hepatitis C with persistently normal alanine aminotransferase (ALT)&#xD;
      levels have been generally excluded from treatment, because the strong conviction that normal&#xD;
      ALT would be synonymous of absence of liver damage. However, recent studies have demonstrated&#xD;
      marked liver fibrosis, including cirrhosis, in patients with HCV and persistently normal ALT&#xD;
      levels. Up to now, just a sigle randomized, controlled, multicenter study was lead to&#xD;
      evaluate the efficacy and safety of combined therapy in patients with chronic hepatitis C and&#xD;
      persistently normal serum ALT levels. Aim of our study is evaluate the efficacy of treatment&#xD;
      and the outcome of treated patients compared with a control group of untreated patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2007</start_date>
  <completion_date type="Anticipated">September 2010</completion_date>
  <primary_completion_date type="Anticipated">September 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the efficacy of treatment and the outcome of treated patients compared with a control group of untreated patients.</measure>
    <time_frame>48-72 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>evaluation of liver fibrosis by Fibroscan after 48-72 weeks of inclusion</measure>
    <time_frame>48-72 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: peginterferon α-2a (40 kDa) plus ribavirin for 24-48 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peg-Interferon alpha2a plus Ribavirin</intervention_name>
    <description>Peg-Interferon alpha2a: 180 micrograms per week Ribavirin:100-1200 mg/daily</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Serologic evidence of chronic hepatitis C infection (repeatedly HCV-RNA positive) with&#xD;
             persistent normal ALT levels documented on at least 3 occasions, in the last 18 months&#xD;
             before screening.&#xD;
&#xD;
          -  Fibroscan performed in the last 3 months&#xD;
&#xD;
          -  Compensated liver disease, Child Pugh score &lt;7&#xD;
&#xD;
          -  Serum HCV-RNA &gt;615 IU/mL&#xD;
&#xD;
          -  Patients who are naïve to any hepatitis C therapy (i.e. have not been previously&#xD;
             treated with an interferon or with IFN plus ribavirin)&#xD;
&#xD;
          -  No clinical or radiological evidence of hepatocellular carcinoma and a serum AFP &lt;100&#xD;
             ng/mL within 2 months of randomisation&#xD;
&#xD;
          -  Negative urine or blood pregnancy test (for women of childbearing potential)&#xD;
             documented within the 24-hour period prior to the first dose of study drug&#xD;
&#xD;
          -  All fertile males and females receiving ribavirin must be using two forms of effective&#xD;
             contraception during treatment and during the 6 months after treatment end&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women with ongoing pregnancy or breast feeding&#xD;
&#xD;
          -  History or other evidence of bleeding from oesophageal varices or other conditions&#xD;
             consistent with decompensated liver disease (Child Pugh B or C)&#xD;
&#xD;
          -  Therapy with any systemic anti-viral, anti-neoplastic or immunomodulatory treatment&#xD;
             (including supraphysiologic doses of steroids and radiation) £6 months prior to the&#xD;
             first dose of study drug&#xD;
&#xD;
          -  History or other evidence of a medical condition associated with chronic liver disease&#xD;
             other than HCV (e.g., hemochromatosis, autoimmune hepatitis, metabolic liver disease,&#xD;
             alcoholic liver disease, toxin exposures)&#xD;
&#xD;
          -  Neutrophil count &lt;1500 cells/mm3 or platelet count &lt;90,000 cells/mm3 at screening&#xD;
&#xD;
          -  Serum creatinine level &gt;1.5 times the upper limit of normal at screening&#xD;
&#xD;
          -  Evidence of current severe psychiatric disease, especially depression within one year&#xD;
             of study entry. Severe psychiatric disease is defined as treatment with an&#xD;
             antidepressant medication or a major tranquilizer at therapeutic doses for major&#xD;
             depression or psychosis, respectively, within 12 months prior to study entry. Patients&#xD;
             with a previous history of the following: a suicidal attempt, hospitalization for&#xD;
             psychiatric disease, or a period of disability due to a psychiatric disease should be&#xD;
             evaluated by a qualified Psychiatrist for study suitability prior to enrolment.&#xD;
&#xD;
          -  History of a severe seizure disorder or current anticonvulsant use History of&#xD;
             immunologically mediated disease, chronic pulmonary disease associated with functional&#xD;
             limitation, severe cardiac disease, major organ transplantation or other evidence of&#xD;
             severe illness, malignancy, or any other conditions which would make the patient, in&#xD;
             the opinion of the investigator, unsuitable for the study&#xD;
&#xD;
          -  History of thyroid disease poorly controlled on prescribed medications, elevated&#xD;
             thyroid stimulating hormone (TSH) concentrations with elevation of antibodies to&#xD;
             thyroid peroxidase and any clinical manifestations of thyroid disease&#xD;
&#xD;
          -  Evidence of severe retinopathy (e.g. CMV retinitis, macula degeneration)&#xD;
&#xD;
          -  Evidence of drug abuse (including excessive alcohol consumption) within 6 months of&#xD;
             study entry&#xD;
&#xD;
          -  Inability or unwillingness to provide informed consent or abide by the requirements of&#xD;
             the study&#xD;
&#xD;
          -  Male partners of women who are pregnant&#xD;
&#xD;
          -  Hgb &lt;12 g/dL in women or &lt;13 g/dL in men at screening&#xD;
&#xD;
          -  Any patient with an increased baseline risk for anemia (e.g. thalassemia,&#xD;
             spherocytosis, history of GI bleeding, etc) or for whom anemia would be medically&#xD;
             problematic&#xD;
&#xD;
          -  Patients with documented or presumed coronary artery disease or cerebrovascular&#xD;
             disease should not be enrolled if, in the judgment of the investigator, an acute&#xD;
             decrease in hemoglobin by up to 4 g/dL (as may be seen with ribavirin therapy) would&#xD;
             not be well-tolerated&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rizzetto Mario</last_name>
    <role>Principal Investigator</role>
    <affiliation>Università degli Studi di Torino - Azienda Ospedaliera San Giovanni Battista di Torino, Molinette,</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>RIZZETTO Mario, MD</last_name>
    <phone>+39-011-6336397</phone>
    <email>m.rizzetto@molinette.piemonte.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>CIANCIO Alessia, MD, PhD</last_name>
    <phone>+39-011-6336224</phone>
    <email>aciancio3@molinette.piemonte.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Università degli Studi di Torino - Azienda Ospedaliera San Giovanni Battista di Torino, Molinette,</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ciancio Alessia, MD, PhD</last_name>
      <phone>+39-0116336224</phone>
      <email>aciancio3@molinette.piemonte.it</email>
    </contact>
    <investigator>
      <last_name>Ciancio Alessia, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>June 2008</verification_date>
  <study_first_submitted>December 14, 2007</study_first_submitted>
  <study_first_submitted_qc>December 14, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 18, 2007</study_first_posted>
  <last_update_submitted>June 3, 2008</last_update_submitted>
  <last_update_submitted_qc>June 3, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2008</last_update_posted>
  <responsible_party>
    <name_title>Prof Mario Rizzetto - Dipartimento di GastroEpatologia - Università degli Studi di Torino</name_title>
    <organization>Università degli Studi di Torino</organization>
  </responsible_party>
  <keyword>Hepatitis C</keyword>
  <keyword>persistently normal ALT</keyword>
  <keyword>pNNALT</keyword>
  <keyword>Theraphy for Hepatitis C</keyword>
  <keyword>Pegylated Interferon</keyword>
  <keyword>Combined therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Interferon alpha-2</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

